The Gut Microbiome’s Surprising Role in Colorectal Cancer, Explained

Colorectal cancer is on course to increase by more than 60% by 2040, with younger populations bearing a disproportionate share of that burden. A comprehensive new review by Dietz, Subramanian, and Staley, published in July 2026 in Clinical Microbiology Reviews, makes a pointed argument: the trillions of bacteria living in the human gut are not passive bystanders in that trend. They are active participants, producing metabolites, hijacking signaling pathways, and in some cases directly pushing cells toward malignancy.

How gut bacteria produce cancer-promoting signals

The microbiome's influence on colorectal cancer (CRC) runs largely through chemistry. Bacteria break down food and produce metabolites, small molecules that circulate through the gut lining and interact with host cells. The review, which draws on a growing body of mechanistic and metagenomic research, identifies three metabolite classes as particularly consequential.

Short-chain fatty acids (SCFAs), produced when gut bacteria ferment dietary fiber, generally protect the colon: they reduce inflammation and reinforce the intestinal barrier. Secondary bile acids tell a different story. Generated when bacteria modify bile acids that the liver produces, they can induce oxidative stress, trigger DNA damage, and switch on proliferative signaling cascades. Tryptophan derivatives, a third class, modulate immune responses in ways that can either restrain or enable tumor growth depending on which microbial species are doing the converting.

Those metabolites feed into signaling pathways that cell biology textbooks flag as canonical cancer drivers: Wnt/β-catenin, NF-κB, STAT3, and PI3K/AKT. Shifts in gut microbiome composition linked to CRC through mechanisms including chronic inflammation, metabolic alteration, and oncogenic signaling have now been confirmed by large-scale genetic sequencing studies.

Three bacterial species directly implicated in tumor development

Not every microbe matters equally. The review singles out three species with the most direct mechanistic links to CRC, and each operates through a distinct route.

Enterotoxigenic Bacteroides fragilis (ETBF) secretes a protein called fragilysin that cleaves E-cadherin on intestinal epithelial cells. The result is activation of STAT3 and β-catenin signaling, creating what the authors describe as a pro-tumorigenic environment. Fusobacterium nucleatum also targets E-cadherin, but additionally promotes inflammation, suppresses anti-tumor immune responses, and accelerates cell proliferation. Escherichia coli carrying the pks genomic island produce a toxin called colibactin that directly damages DNA. Together, these pathogenic bacteria contribute to CRC through chronic inflammation, genotoxic metabolite production, and immune evasion, a mechanistic picture that has now been replicated across multiple research groups.

On the other side of the ledger, patients with CRC consistently show depleted levels of Lactobacillus, Bifidobacterium, and Faecalibacterium, species associated with anti-inflammatory and barrier-protective effects. Dysbiosis in CRC is not just a matter of more harmful bacteria; it is also a matter of fewer protective ones.

Metagenomic profiling of tumor-associated microbiomes

Understanding which bacterial signatures predict cancer risk requires tools that can survey thousands of species simultaneously. High-throughput shotgun metagenomic sequencing has advanced that understanding considerably, allowing researchers to move beyond culture-based methods and catalog microbial communities at a resolution that was impossible a decade ago.

That resolution is now yielding clinically relevant signals. The review notes that machine learning models trained on gut microbiome profiles can identify adenomatous polyps, the precursor lesions that precede most sporadic CRC cases, as well as early-stage cancer. Because over 80% of CRC cases are sporadic rather than hereditary, a non-invasive microbiome-based screening signal could reach a large population. Microbiome signatures also appear capable of distinguishing CRC from inflammatory bowel disease (IBD), a clinically important differentiation since the two conditions share some symptoms.

The review is careful not to overstate what metagenomic signatures currently deliver. Identifying a microbial pattern associated with CRC is not the same as understanding the causal chain that connects specific microbial taxa to tumor growth. That causal hierarchy remains, in the authors' framing, incompletely understood.

Why the causal picture is still incomplete

Several layers of complexity stand between the current evidence and a clean mechanistic model. Individual microbiomes vary enormously between people, and that heterogeneity makes it difficult to isolate the contribution of any single species or metabolite. Metabolic redundancy compounds the problem: different bacterial species can produce the same metabolite, so removing one organism does not necessarily eliminate its chemical output.

Diet, genetics, and medication history all reshape microbiome composition and confound interpretation. The review also flags a technical gap: most of the mechanistic work focuses on bacteria, while the fungal microbiome and the gut virome remain far less studied. Technical and regulatory hurdles have slowed research into how fungi and viruses contribute to CRC risk, leaving a substantial portion of the microbial ecosystem underexplored.

Developing microbiome-based screening tools for CRC will require large meta-cohorts and advanced computational approaches capable of identifying reproducible early-lesion signatures across diverse populations.

Microbiota-targeted therapies from probiotics to quorum quenching

The therapeutic implications of this research are already generating clinical activity. Prebiotics and probiotics are the most established interventions, with evidence suggesting they can restore some protective microbial diversity. Probiotics and next-generation postbiotics represent a promising complementary strategy for restoring gut microbiota and promoting anticarcinogenic pathways in CRC patients.

Fecal microbiota transplantation (FMT), which transfers a donor's microbial community to a recipient, is a more aggressive approach with a documented track record in other conditions and growing interest in oncology. The review also highlights an experimental strategy called quorum quenching, which disrupts the chemical signaling that bacteria use to coordinate group behavior. By blocking quorum sensing, it may be possible to prevent pathogenic species from mounting the coordinated responses that promote tumor growth.

The microbiome also appears to influence how patients respond to cancer treatment itself. Gut microbiota-related treatment strategies including modulation of immune response for enhanced anti-tumor immunity are an active area of investigation, raising the prospect that microbiome profiling could one day guide chemotherapy or immunotherapy decisions. That prospect depends on resolving the causal questions the review identifies as still open, but the trajectory of the field suggests those answers are within reach.

Evidence rating

EMERGING — 84/100

Caveats:

• This is a narrative review, not a new clinical trial — it synthesizes existing research but does not generate original data.
• The authors note that causal hierarchies linking specific microbial taxa, metabolites, and host pathways remain incompletely established.
• Interindividual microbiome variability, metabolic redundancy, and the influence of diet and genetics make direct mechanistic conclusions difficult.
• Funding for this review was not disclosed by the authors.

Narrative review synthesizing current research on gut microbiome contributions to colorectal cancer development and progression. Draws on multiple independent studies and identifies named bacterial species, metabolites, and host signaling pathways, but does not generate primary data and cannot establish causation on its own. Key mechanistic claims are supported by converging lines of evidence, though the authors acknowledge conflicting findings and incomplete causal hierarchies in the field.

References

1. Matthew Dietz, Subbaya Subramanian, Christopher Staley (2026). The gut microbiome and colorectal cancer. Clinical Microbiology Reviews. https://doi.org/10.1128/cmr.00332-25
2. Miriam Tudorache, Andreea-Ramona Treteanu, Gratiela Gradisteanu Pircalabioru, Irina-Oana Lixandru-Petre, Alexandra Bolocan, Octavian Andronic (2025). Gut Microbiome Alterations in Colorectal Cancer: Mechanisms, Therapeutic Strategies, and Precision Oncology Perspectives. Cancers. https://doi.org/10.3390/cancers17142294
3. Yue Li, Xingyu Shen, Deqiang Wang, Kang Sun (2026). The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies. Discover Oncology. https://doi.org/10.1007/s12672-025-04367-1
4. Amir Torshizi Esfahani, Nikta Zafarjafarzadeh, Fatemeh Vakili, et al. (2025). Gut microbiome in colorectal cancer: metagenomics from bench to bedside. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf026
5. Andrea Severino, Stefano Andrea Marchitto, Piergiorgio Bisegna, et al. (2025). Measuring gut microbiome as a colorectal cancer screening tool: potential and challenges. Expert Review of Gastroenterology & Hepatology. https://doi.org/10.1080/17474124.2025.2592078
6. Monika Kvakova, Anna Kamlarova, Jana Stofilova, Veronika Benetinova, Izabela Bertkova (2022). Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v28.i27.3370
7. Bhaskar Roy, Kunfeng Cao, Chabungbam Orville Singh, Xiaodong Fang, Huanming Yang, Dong Wei (2025). Advances in gut microbiota-related treatment strategies for managing colorectal cancer in humans. Cancer Biology & Medicine. https://doi.org/10.20892/j.issn.2095-3941.2024.0263